Evidence map›Paper›PMID 35135467›Full record

ArticleCurrent radiopharmaceuticals2022

Toxicity and Tolerability of

Alireza Khatami, Golmehr Sistani, Duncan E K Sutherland, Sarah DeBrabandere, Robert H Reid, David T Laidley

Abstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Current radiopharmaceuticals, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Inter-institutional variability in kidney dosimetry duringRadiological physics and technology · 2026
    Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Alireza KhatamiDivision of Nuclear Medicine, Department of Medical Imaging, Western University, London, ON N645C1, Canada.
Golmehr SistaniDivision of Nuclear Medicine, Department of Medical Imaging, Western University, London, ON N645C1, Canada.
Duncan E K SutherlandDivision of Nuclear Medicine, Department of Medical Imaging, Western University, London, ON N645C1, Canada.
Sarah DeBrabandereDivision of Nuclear Medicine, Department of Medical Imaging, Western University, London, ON N645C1, Canada.
Robert H ReidDivision of Nuclear Medicine, Department of Medical Imaging, Western University, London, ON N645C1, Canada.
David T LaidleyDivision of Nuclear Medicine, Department of Medical Imaging, Western University, London, ON N645C1, Canada.

Funding

Cancer Care Ontario CCO Canada 172567
6 · The paper itself

Abstract

backgroundPeptide receptor radionuclide therapy (PRRT) has been recently approved for advanced, metastatic, or progressive neuroendocrine tumors (NETs).

objectiveThis study reports the adverse events (AEs) observed with patient-tailored administered activity.

methodsFifty-two PRRT naive patients were treated with 177Lu-DOTATATE. The administered activity ranges between 2.78 and 5.55 GBq/cycle using the patient's unique characteristics (age, symptoms, blood work, and biomarkers).

resultsThe protocol was well tolerated with the overwhelming majority of participants being forty- six (88%), completing all 4 induction therapy cycles. The median cumulative administered activity was 19.6 GBq (ranged 3.8-22.3 GBq). A total of 42/52 (81%) reported at least one symptom, and 43/52 (83%) had evidence of biochemical abnormality at enrollment that would meet grade 1 or 2 criteria for AEs. These symptoms only slightly increase with treatment to 50/52 (96%) and 51/52 (98%), respectively. The most common symptoms were mild fatigue (62%), shortness of breath (50%), nausea (44%), abdominal pain (38%), and musculoskeletal pain (37%). The most common biomarker abnormalities were mild anemia (81%), reduced estimated glomerular filtration rate (eGFR) (58%), increased alkaline phosphatase (ALP) (50%), and leukopenia (37%). Of critical importance, no 177Lu-DOTATATE related grade 3 or 4 AEs were observed.

conclusionTailoring the administered activity of 177Lu-DOTATATE to the individual patient with a variety of NETs is both safe and well-tolerated. No patient developed severe grade 3 or 4 AEs. Most patients exhibit symptoms or biochemical abnormality before treatment and this only slightly worsens following induction therapy.

Indexed as

Neuroendocrine TumorsOrganometallic CompoundsClinical Trials, Phase II as TopicHeterocyclic Compounds, 1-RingHumansOctreotidePositron-Emission TomographyRadionuclide ImagingRadiopharmaceuticalsRegistries1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidcopper dotatate CU-64Heterocyclic Compounds, 1-RingOctreotideOrganometallic CompoundsRadiopharmaceuticalsDOTATAELu-177NETneuroendocrine tumorpeptide receptor radionuclide therapyPRRTsafetyToxicity

Identifiers

PMID35135467
PMCPMC9900697

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.